Corbus Pharmaceuticals Holdings (CRBP) Company Report

Corbus Pharmaceuticals is advancing its ADC, CRB701, with 2026 milestones including maturing durability data and FDA discussions for registrational pathways in second-line head and neck and cervical cancers, alongside emerging data for front-line head and neck in combination with Keytruda.
The company presented positive Phase 1A/B SADMAD data for its obesity drug, CRB913, demonstrating a very mild GI adverse event profile and no clinical neuropsychiatric events, differentiating it from prior CB1 inverse agonists.
CRB913 showed significant efficacy, with an average of nearly 3% weight loss after one week of dosing in high BMI individuals, and further highly informative data from a US-only study is anticipated by late summer 2026.
Corbus Pharmaceuticals reported a cash position of $172 million, providing a financial runway into 2028.

Jan 15, 2026, 4:15 PM

Transcript

Corbus Pharmaceuticals Outlines 2026 Milestones and Provides CRB-913 Data Update

CRBP

New Projects/Investments

Guidance Update

Corbus Pharmaceuticals (CRBP) is advancing its ADC, CRB-701, with key milestones in 2026 including presenting maturing data and engaging in regulatory discussions with the FDA for second-line head and neck and cervical cancer, and emerging data for front-line head and neck anticipated later in the year.
Early data for the obesity drug candidate, CRB-913, demonstrated a nearly 3% weight loss in one week in a high BMI cohort, coupled with a very mild GI adverse event profile and no neuropsychiatric adverse events, distinguishing it from other CB1 inverse agonists.
A highly informative dataset for CRB-913, providing granular details on safety, dose response, and projected weight loss up to a year, is expected in late summer 2026 from a US-only study.
The company reported $172 million in cash, providing a financial runway into 2028 for its development programs.

Jan 15, 2026, 4:15 PM

Transcript

Corbus Pharmaceuticals Holdings, Inc. Updates on Pipeline Progress and Financial Position

CRBP

New Projects/Investments

Guidance Update

Corbus Pharmaceuticals Holdings, Inc. reported $173 million in cash, cash equivalents, and investments as of November 3, 2025, with approximately 17.6 million common shares issued and outstanding.
The company's next-generation Nectin-4 targeting ADC, CRB-701, received FDA Fast Track Designation for HNSCC and Cervical cancer and demonstrated superior objective response rates compared to peers in HNSCC (47.6% vs. 36% for Petosemtamab and 23.9% for PADCEV®) and Cervical Cancer (37.5% vs. 17.8% for Tivdak®). Key upcoming milestones include a monotherapy update in Q1 2026 and the start of registrational studies by mid-2026.
For CRB-913, a peripherally restricted CB1R inverse agonist for obesity, the Phase 1b study (CANYON-1) is expected to complete in Summer 2026 , building on Phase 1a data that showed 2.9% average placebo-adjusted weight loss at day 14 and a favorable GI tolerability profile.
The company also expects Phase 1 dose escalation data for CRB-601, an Anti-αvβ8 mAb for solid tumors, in Q1 2026.

Jan 12, 2026, 12:26 PM

8-K

Corbus Pharmaceuticals Discusses CRB-913 SAD-MAD Study Results and Initiates Phase 1b CANYON-1 Study

CRBP

Product Launch

New Projects/Investments

Corbus Pharmaceuticals announced that its drug candidate, CRB-913, a CB1 inverse agonist, demonstrated a "highly, highly excluded from the brain" profile compared to Rimonabant and Monlunabant, with a brain-to-plasma ratio 1/50th of Rimonabant and 1/15th of Monlunabant's brain levels in mice. This peripheral restriction was associated with a favorable safety and tolerability profile, including an "unusually benign GI adverse event profile" with only a single case of mild diarrhea, and no cases of suicidality, depression, or dysphoria.
In a 14-day study involving participants with obesity, CRB-913 achieved a placebo-adjusted weight loss of "just under 3%". This weight loss began early, deepened over time, and was not attributed to gastrointestinal adverse events.
The company has initiated CANYON-1, a Phase 1b study, which will involve titration of doses (20, 40, and 60 mg) over three months, aiming to enhance tolerability. This study will also implement stricter screening criteria, including the exclusion of participants with high PHQ-9 scores at baseline.
Participants in the study positively reported a reduction in food cravings or "food noise". Experts highlighted the significance of this effect in obesity management, as it addresses the anticipation and pervasive thoughts about food that contribute to increased consumption.

Dec 11, 2025, 1:00 PM

Transcript

Corbus Pharmaceuticals Reports Positive CRB-913 Study Results and Initiates Phase I-B Trial

CRBP

New Projects/Investments

CRB-913, Corbus Pharmaceuticals' CB1 inverse agonist, demonstrated a favorable safety and tolerability profile in its SAD-MAD study, exhibiting significantly lower gastrointestinal and neuropsychiatric adverse events compared to monlunabant and first-generation CB1 inverse agonists.
The study showed early and deepening weight loss, with participants in obese cohorts achieving a 2.9% placebo-adjusted weight loss in 14 days, which was not attributed to GI adverse events.
Corbus Pharmaceuticals has initiated CANYON-1, a Phase I-B study, to further evaluate CRB-913, utilizing a titrated dosing regimen (20 mg, 40 mg, 60 mg) over three months.

Dec 11, 2025, 1:00 PM

Transcript

CRBP Presents Favorable Safety and Early Efficacy Data for Investigational Obesity Drug CRB-913

CRBP

New Projects/Investments

CRBP's investigational drug, CRB-913, demonstrated a favorable safety and tolerability profile in a SAD-MAD study, exhibiting an unusually benign gastrointestinal (GI) adverse event profile with only a single case of mild diarrhea, and no observed suicidality or depression, a significant contrast to Monlunabant.
Early data from the study showed 4% weight loss at 14 days, which is considered remarkable given the FDA's 5% weight loss criteria typically applied at three months for drug approval, and this weight loss was not driven by GI adverse events.
The drug's high peripheral restriction, with 1/15 of the brain levels compared to Monlunabant at the same dose, suggests the weight loss effect is primarily on peripheral organs of metabolism.
Participants reported a reduction in food cravings or "food noise," a significant benefit that impacts the dopaminergic reward system and helps patients achieve weight loss goals.
CRBP has initiated CANYON-1, a Phase 1b study, which will utilize titration with doses of 20, 40, and 60mg, marking a novel approach for a CB1 inverse agonist, aiming to improve tolerability and potentially achieve similar efficacy to Monlunabant at lower doses.

Dec 11, 2025, 1:00 PM

Transcript

Corbus Pharmaceuticals Reports Positive Phase 1a Results for CRB-913 and Provides Oncology Pipeline Update

CRBP

Product Launch

New Projects/Investments

Corbus Pharmaceuticals announced the completion of the Phase 1a study of CRB-913, an oral CB1 inverse agonist for obesity, which showed a favorable safety profile and a placebo-adjusted mean weight loss of 2.9% at Day 14 in obese participants.
Following these results, a Phase 1b dose-finding study (CANYON-1) for CRB-913 in people with obesity has been initiated, with completion anticipated in summer 2026.
The company also provided updates on its oncology pipeline, including CRB-701, which demonstrated an Overall Response Rate (ORR) of 47.6% in HNSCC, 37.5% in Cervical Cancer, and 55.6% in Bladder Cancer at the 3.6 mg/kg dose, and received FDA Fast Track Designation for HNSCC and Cervical Cancer.
As of November 3, 2025, Corbus Pharmaceuticals reported $173 million in cash, cash equivalents, and investments.

Dec 11, 2025, 12:22 PM

8-K

Corbus Pharmaceuticals Reports Positive Phase 1a Results for Obesity Drug CRB-913 and Initiates Phase 1b Study

CRBP

New Projects/Investments

Corbus Pharmaceuticals completed its Phase 1a study of CRB-913, an oral CB1 inverse agonist for obesity, demonstrating a favorable safety and tolerability profile across all doses, with no serious adverse events or GI intolerability and stable neuropsychiatric assessments.
The Phase 1a study showed a placebo-adjusted mean weight loss of 2.9% at Day 14 in a dedicated cohort of people with obesity (n=12).
The company has initiated a 12-week Phase 1b dose-finding study (CANYON-1) in people with obesity, with completion anticipated in summer 2026.

Dec 11, 2025, 12:00 PM

Press Release

Corbus Pharmaceuticals to Report Phase 1a Study Results for CRB-913

CRBP

New Projects/Investments

Corbus Pharmaceuticals Holdings Inc. (CRBP) will release results from its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913 prior to market open on Thursday, December 11, 2025.
CRB-913 is an oral small molecule inverse agonist of the CB1 receptor, developed for the treatment of obesity.
The company will host a conference call and live webcast on December 11, 2025, at 8:00 am ET to discuss the Phase 1a data.
Preclinical models indicate CRB-913 is a highly peripherally restricted CB1 inverse agonist with significantly reduced brain penetration compared to earlier experimental drugs, aiming to mitigate neuropsychiatric adverse events.

Dec 10, 2025, 9:01 PM

Press Release

Corbus Pharmaceuticals Provides Business Overview and Upcoming Milestones

CRBP

New Projects/Investments

Guidance Update

Corbus Pharmaceuticals, a drug development company, is focused on oncology with its Nectin-4 ADC program (CRB-701) and obesity with its CB1 program.
Key upcoming milestones for the CRB-701 (ADC) program include a Q1 2026 regulatory update for its pivotal study, and mid-2026 and second-half 2026 data readouts for various head and neck and cervical cancer indications.
For the CB1 (obesity) program, an imminent SAD/MAD data press release and mid-2026 90-day dose-ranging study data are anticipated.
The company has extended its cash runway into 2028 and currently has just under $180 million in the bank.
Management's investment priorities are the second-line monotherapy head and neck program, followed by cervical, then the front-line combo head and neck, and finally the 90-day CB1 study.